CN103127089A - Application of Eryngiolide A in medicines curing or preventing kidney fibrosis - Google Patents
Application of Eryngiolide A in medicines curing or preventing kidney fibrosis Download PDFInfo
- Publication number
- CN103127089A CN103127089A CN2012104145636A CN201210414563A CN103127089A CN 103127089 A CN103127089 A CN 103127089A CN 2012104145636 A CN2012104145636 A CN 2012104145636A CN 201210414563 A CN201210414563 A CN 201210414563A CN 103127089 A CN103127089 A CN 103127089A
- Authority
- CN
- China
- Prior art keywords
- eryngiolide
- kidney fibrosis
- medicines
- curing
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides application of Eryngiolide A in preparation of medicines curing and preventing kidney fibrosis, and belongs to the medicines new use technical field. New use of the Eryngiolide A in preparation of medicines curing or preventing kidney fibrosis is made public for the first time, due to the fact that the skeleton type is completely novel, and the Eryngiolide A has an unexpectedly kidney fibrosis inhibitory activity. Probability of other compounds giving any revelation for the Eryngiolide A does not exist, outstanding substantive features are provided, meanwhile, prominent improvement is evidently possessed in preventing and curing kidney fibrosis.
Description
Technical field
The present invention relates to a kind of new medicine use, relate to particularly the application of Eryngiolide A in the medicine of preparation treatment or preventing renal fibrosis.
Background technology
Renal fibrosis (comprising kidney region fibrosis and glomerular sclerosis) is the main pathological basis of the kidney damage final stage that causes of a variety of causes, the renal fibrosis mechanism is comparatively complicated, relevant with many factors, wherein main and the celliferous propagation of extracellular matrix cell and activation, vaso-active substance, cytokine and extracellular matrix conversion are unbalance relevant, so kidney region fibrosis is almost the common pathway that former or secondary kidney disease proceed to end stage renal failure.
the compd E ryngiolide A that the present invention relates to is one and delivered (Wang in 2012, S. J. et al., 2012. Eryngiolide A, a Cytotoxic Macrocyclic Diterpenoid with an Unusual Cyclododecane Core Skeleton Produced by the Edible Mushroom Pleurotus eryngii. Organic Letters 14 (14), 3672 – 3675.) New skeleton compound, this compound has brand-new framework types, present purposes only relates to the cytotoxic activity (Wang of cancerous cell, S. J. et al., 2012. Eryngiolide A, a Cytotoxic Macrocyclic Diterpenoid with an Unusual Cyclododecane Core Skeleton Produced by the Edible Mushroom Pleurotus eryngii. Organic Letters 14 (14), 3672 – 3675.), belong to open first for the purposes of the Eryngiolide A that the present invention relates in preparation treatment or preventing renal fibrosis medicine, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for renal fibrosis, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, the control that is used for simultaneously renal fibrosis obviously has significant progress.
Summary of the invention
The invention provides the application of Eryngiolide A in the medicine of preparation prevention or treatment renal fibrosis.
Described compd E ryngiolide A structure is as shown in formula I:
The purposes of the Eryngiolide A that the present invention relates in preparation treatment or preventing renal fibrosis medicine belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for renal fibrosis, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously renal fibrosis obviously has significant progress.
The specific embodiment
The preparation method of compd E ryngiolide A involved in the present invention is referring to document (Wang, S. J. et al., 2012. Eryngiolide A, a Cytotoxic Macrocyclic Diterpenoid with an Unusual Cyclododecane Core Skeleton Produced by the Edible Mushroom Pleurotus eryngii. Organic Letters 14 (14), 3672 – 3675.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compd E ryngiolide A tablet involved in the present invention:
Get 20 and digest compound Eryngiolide A, add conventional adjuvant 180 grams that prepare tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compd E ryngiolide A capsule involved in the present invention:
Get 20 and digest compound Eryngiolide A, add the conventional adjuvant such as starch 180 grams that prepare capsule, mixing is encapsulatedly made 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
The impact of test Eryngiolide A on the Rats Undergoing Unilateral Urethral Ligation kidney region fibrosis
1.1 material
Benazepril, Novartis Pharma AG produces; Hydroxyproline (HYP) test kit, biotech firm is built up in Nanjing; Fibronectin (FN) test kit is available from the Shanghai institute of Biological Products.
Laboratory animal: regular grade Wistar rat, male, body weight 150-200g, SD rat.
1.2 test method and result
90 of rats, divide 9 groups at random, it is sham operated rats, model group, benazepril gavage 10mg/kg group, Eryngiolide A intravenous injection 2.5 mg/kg groups, Eryngiolide A intravenous injection 5 mg/kg groups, Eryngiolide A intravenous injection 25 mg/kg groups, Eryngiolide A gavage 5mg/kg group, Eryngiolide A gavage 10mg/kg group, Eryngiolide A gavage 50mg/kg group, 1 week of animal feeding, each rat with 10% chloral hydrate 3.0mL/kg intraperitoneal injection of anesthesia after, with the Rat Right lateral position fixing with operating-table on, use iodine tincture after cropping, 75% alcohol disinfecting field of operation, row left side abdomen otch, successively cut skin, muscle and each layer of stomach wall, expose and separate the left side ureter, sham operated rats is only cut abdominal cavity and free left side ureter, but not ligation and cutting off, other respectively organize rat 4-0 silk thread ligation twice, upper one ligation point is positioned at left inferior pole of kidney level, then cut off ureter at twice ligation point, layer-by-layer suture, postoperative was put to death each treated animal after 10% chloral hydrate anesthesia in 10 days, get blood, press Fibronectin and measure explanation mensuration explanation fiber connexin (FN).Normal saline is left and taken left kidney after lavation repeatedly, and nephridial tissue is fixed through 4% paraformaldehyde buffer.Cut appropriate nephridial tissue, press the explanation of hydroxyproline kit measurement and measure hydroxyproline.
Routine pathology is learned and to be examined 1. perusal: sham operated rats kidney color is scarlet, shows smoothly, and peplos gloss is without adhesion.Other respectively organize the Kidney Volume increase, and color is pale, shows to be graininess, similar human body branny kidney, the adhesion of a few regions kidney peplos.2. light microscopy checking: sham operated rats nephron result is clear, and glomerular capsule is without expansion or cell infiltration.The large stretch of renal tubular necrosis of model control group, the hyperplasia of kidney interstitial fibers, tubular ectasia, in a large amount of brown color shading materials or the downright bad epithelial cell that comes off are arranged, the glomerule decreased number, part glomerule fibrosis and with the adhesion of bowman's capsule wall, blister cavities disappears.Administration respectively organizes pathological changes and model control group is similar, but all has morphology in various degree to improve, and especially with heavy dose of each group of Eryngiolide A gavage significantly, with model control group, notable difference is arranged relatively.
The impact of table 1 rosmarinic acid on the Rats Undergoing Unilateral Urethral Ligation kidney region fibrosis
* p＜0.05, compare with model group in * * p＜0.01
FN, HYP carry out the T check to each group.The results are shown in Table 1, Eryngiolide A intravenous injection 5 mg/kg organize, Eryngiolide A intravenous injection 25 mg/kg organize, Eryngiolide A gavage 10mg/kg organizes, Eryngiolide A gavage 50mg/kg group reduces FN, HYPP level (comparing P＜0.05 or 0.01 with model control group).
Conclusion: Eryngiolide A can significantly reduce the rising of kidney region fibrosis FN, HYPP level, suppresses kidney region fibrosis, can be used for preparing anti-renal fibrosis medicine.
Claims (1)
1.Eryngiolide the application of A in treatment or the medicine of preventing renal fibrosis, described compd E ryngiolide A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104145636A CN103127089A (en) | 2012-10-25 | 2012-10-25 | Application of Eryngiolide A in medicines curing or preventing kidney fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104145636A CN103127089A (en) | 2012-10-25 | 2012-10-25 | Application of Eryngiolide A in medicines curing or preventing kidney fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103127089A true CN103127089A (en) | 2013-06-05 |
Family
ID=48487964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104145636A Pending CN103127089A (en) | 2012-10-25 | 2012-10-25 | Application of Eryngiolide A in medicines curing or preventing kidney fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127089A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103462992A (en) * | 2013-09-06 | 2013-12-25 | 张关莲 | Application of Aphanamgrandiol A in preparation of medicaments for treating and preventing renal fibrosis |
-
2012
- 2012-10-25 CN CN2012104145636A patent/CN103127089A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| WANG, S. J. ET AL: "Eryngiolide A, a Cytotoxic Macrocyclic Diterpenoid with an Unusual Cyclododecane Core Skeleton Produced by the Edible Mushroom Pleurotus eryngii", 《ORGANIC LETTERS》 * |
| 刘庆宝: "《泗阳名品》", 31 December 2001 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103462992A (en) * | 2013-09-06 | 2013-12-25 | 张关莲 | Application of Aphanamgrandiol A in preparation of medicaments for treating and preventing renal fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105287546A (en) | Use of Virosaines B in preparation of drug for treating and preventing renal fibrosis | |
| CN103127089A (en) | Application of Eryngiolide A in medicines curing or preventing kidney fibrosis | |
| CN103585149B (en) | Application of Nitrosporeusines A in medicines for treating and preventing renal fibrosis | |
| CN102861063B (en) | Application of Houttuynoid C in medicine for treating or preventing renal fibrosis | |
| CN102861072B (en) | Application of Houttuynoid A in medicine for treating or preventing renal fibrosis | |
| CN102872130B (en) | Application of Houttuynoid D in drug for preventing or treating renal fibrosis | |
| CN107854461A (en) | Apigenin is preparing the application in treating and preventing kidney fibrosis medicine | |
| CN105125568A (en) | Medicine for treating and preventing renal fibrosis and application of medicine | |
| CN102861085B (en) | Application of Houttuynoid E in medicine for treating or preventing renal fibrosis | |
| CN105395541A (en) | Applications of Perovskone B in preparation of medicines treating or preventing renal fibrosis | |
| CN103599095B (en) | The application of Hippolachnin A in treatment and preventing renal fibrosis medicine | |
| CN102872042B (en) | Application of Gypensapogenin B in medicaments for treating or preventing renal fibrosis | |
| CN103356659B (en) | The application of Chukrasone A in the medicine preparing treatment or preventing renal fibrosis | |
| CN103251603A (en) | Application of Myriberine A in preparation of medicines for treating and preventing renal fibrosis | |
| CN106265691A (en) | Friedolanostanes application in preparation treats and prevents renal fibrosis medicine | |
| CN103585153B (en) | Use of Caesanines D in drugs for treating and preventing renal fibrosis | |
| CN103520181B (en) | The application of Phyllanthoid A in preparation treatment and preventing renal fibrosis medicine | |
| CN103462992B (en) | Application of Aphanamgrandiol A in preparation of medicaments for treating and preventing renal fibrosis | |
| CN103381159A (en) | Applications of Chukrasone B in medicines used for treating or preventing renal fibrosis | |
| CN103463005B (en) | Application of racemosins A in preparation of medicine treating or preventing renal fibrosis | |
| CN103120677A (en) | Application of Aphanamixoid A in medicine for treating or preventing renal fibrosis | |
| CN103356569A (en) | Application of Sarcaboside B in medicine used for treating or preventing renal fibrosis | |
| CN103356588A (en) | Application of Sarcaboside A in preparing medicine for treating or preventing renal fibrosis | |
| CN105326846A (en) | Application of Penicillisterol in preparing renal fibrosis treatment and prevention medicine | |
| CN105476986A (en) | Application of Volvalerelactones B to preparation of medicines for treating and preventing renal fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130605 |